PALM BEACH, Florida, October 3, 2017 /PRNewswire/ --
The iShares Nasdaq Biotechnology (IBB) is up over 24% in 2017 and the growth in development of new treatment and therapy needs, as well as the ongoing and increasing need for the newest biotech drugs as Baby Boomer generation continues to age, are growth drivers for the positive outlook in the biotech industry over the long term. Many industry professionals believe overall gains in health care and pharma sectors have helped lift major indexes higher pointing to continued gains for companies such as: Moleculin Biotech Inc. (NASDAQ: MBRX), Endocyte Inc. (NASDAQ: ECYT), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), Arbutus Biopharma Corporation (NASDAQ: ABUS) and Zogenix Inc. (NASDAQ: ZGNX).
Moleculin Biotech, Inc., (NASDAQ: MBRX), a clinical stage pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on license agreements with The University of Texas System on behalf of the M.D. Anderson Cancer Center, today announced that it has entered into an agreement to conduct its clinical trial to study Annamycin for the treatment of acute myeloid leukemia (AML) with the first of several hospitals desiring to be treatment centers.
"Now that our IND (investigational new drug) application is approved, the race is on to open treatment centers and begin recruiting patients," commented Walter Klemp, Chairman and CEO of Moleculin. "We have identified 14 treatment sites that meet our criteria and have expressed an interest in participating, so there will be much more of this to come." Read this and more news for Moleculin Biotech at: http://www.marketnewsupdates.com/news/mbrx.html
"This first facility is a hematology clinic in a major hospital in Poland," continued Mr. Klemp. "Because of the difference in process in Poland compared with the US, we were able to get this site signed up very shortly following the approval of our IND. We anticipate announcing additional sites over the coming months."
Moleculin entered into this first agreement with a hospital in Poznan, Poland (Hospital of the Transfiguration of the Lord - Medical University in Poznan, Department of Hematology and Marrow Transplantation). The ability to treat patients in this and other Polish sites will require a separate regulatory approval in Poland based on the approved US IND. This is one of seven planned treatment sites in Poland.
In other biotech market developments and positive performances:
Endocyte Inc. (NASDAQ: ECYT) close up over 157% on Monday trading more than 53 million shares by the market close. ECYT was also up in afterhours trading yesterday. The company announced this week the completion of an exclusive worldwide license of PSMA-617 from ABX GmbH. Endocyte intends to move quickly into Phase 3 development of[ 177]Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of patients with metastatic castration-resistant prostate cancer (mCRPC). Lu-PSMA-617 delivers the short-range beta-emitting radioactive isotope lutetium (Lu) selectively to tumor cells while by-passing non-PSMA-expressing healthy cells with encouraging efficacy and safety results. As highlighted in roughly 20 peer reviewed publications of studies in the post-chemotherapy compassionate use setting, Lu-PSMA-617 has consistently demonstrated a PSA response (defined as greater than 50% decline from baseline) in 40% to 60% of patients, and a RECIST response rate in soft tissue disease of between 40% and 50%.
Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) closed up over 32% on Monday trading over 12.6 Million shares by the market close. The company announced that during the company's mid-cycle meeting with the U.S. Food and Drug Administration (FDA) the FDA indicated that, at this point, it is not planning to hold an Oncology Drugs Advisory Committee (ODAC) meeting to discuss the New Drug Application (NDA) for fostamatinib in patients with chronic or persistent immune thrombocytopenia (ITP). Additionally, the FDA indicated that it anticipates meeting the Prescription Drug User Fee Act (PDUFA) action date for the application review, which is April 17, 2018. In an earlier communication, the FDA had conditionally approved the proprietary name Tavalisse[TM]. "Since we submitted our NDA this spring, we have worked collaboratively with the FDA to answer routine questions as they arise," said Anne-Marie Duliege, MD, Executive Vice President and Chief Medical Officer of Rigel. "Our positive interactions with the FDA, including their customary biomedical monitoring (BIMO) inspections at our facilities and clinical sites, are in-line with our expectations and have progressed well."
Arbutus Biopharma Corporation (NASDAQ: ABUS) closed Monday up over 16% on over 1.7 million shares traded by market close as was also up in afterhours trading. Arbutus Biopharma, an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, announced last week topline results of the bi-weekly dosing segment of Cohort 4 of the Phase II study of its RNAi agent, ARB-1467. In the bi-weekly dosing segment of Cohort 4, twelve HBeAg negative chronically infected HBV patients on stable nucleotide therapy were given five doses of ARB-1467 on a bi-weekly dosing schedule. All twelve patients in Cohort 4 experienced reductions in serum HBsAg levels, with an average reduction in serum HBsAg of 1.4 log10, which was greater than that observed with monthly dosing in Cohorts 1-3. Seven of the twelve patients met the predefined response criteria (at least 1 log10 reduction in serum HBsAg level and a serum HBsAg level below 1000 IU/mL) at or before day 71.
Zogenix Inc. (NASDAQ: ZGNX) came to a close up over 10% on Monday with over 11.2 million shares traded on the day. The company recently announced positive top-line results from its first Phase 3 trial (Study 1) for its investigational drug, ZX008 (low-dose fenfluramine hydrochloride), for the treatment of Dravet syndrome. The trial met its primary objective of demonstrating that ZX008, at a dose of 0.8 mg/kg/day, is superior to placebo as adjunctive therapy in the treatment of Dravet syndrome in children and young adults based on change in the frequency of convulsive seizures between the 6-week baseline observation period and the 14-week treatment period (p<0.001). ZX008 0.8 mg/kg/day also demonstrated statistically significant improvements versus placebo in all key secondary measures, including the proportion of patients with clinically meaningful reductions in seizure frequency and longest seizure-free interval. The same analyses comparing a 0.2 mg/kg/day ZX008 dose versus placebo also demonstrated statistically significant improvement compared with placebo.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated thirty-nine hundred dollars for news coverage of the current press release issued by Moleculin Biotech Inc. by the company. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements.
Media Contact email: email@example.com